title: Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.
authors.forename: P N
authors.initials: PN
authors.lastname: Maton
authors.forename: T M
authors.initials: TM
authors.lastname: O'Dorisio
authors.forename: B A
authors.initials: BA
authors.lastname: Howe
authors.forename: K E
authors.initials: KE
authors.lastname: McArthur
authors.forename: J M
authors.initials: JM
authors.lastname: Howard
authors.forename: J A
authors.initials: JA
authors.lastname: Cherner
authors.forename: T B
authors.initials: TB
authors.lastname: Malarkey
authors.forename: M J
authors.initials: MJ
authors.lastname: Collen
authors.forename: J D
authors.initials: JD
authors.lastname: Gardner
authors.forename: R T
authors.initials: RT
authors.lastname: Jensen
mesh_terms: D000138:Acidosis / Q000188:drug therapy / Q000209:etiology; D007516:Adenoma, Islet Cell / Q000150:complications* / Q000378:metabolism; D000368:Aged; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007008:Hypokalemia / Q000188:drug therapy / Q000209:etiology; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D009037:Motilin / Q000097:blood; D009496:Neurotensin / Q000097:blood; D015282:Octreotide; D010190:Pancreatic Neoplasms / Q000150:complications* / Q000378:metabolism; D010191:Pancreatic Polypeptide / Q000097:blood; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014660:Vasoactive Intestinal Peptide / Q000097:blood
chemical_list: D014660:Vasoactive Intestinal Peptide; D009496:Neurotensin; D013004:Somatostatin; D009037:Motilin; D010191:Pancreatic Polypeptide; D015282:Octreotide